Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery

This study tests two immunotherapy drugs — cemiplimab and fianlimab — given before surgery to people with large or locally advanced basal cell carcinoma of the head and neck that cannot be safely removed without causing major disfigurement, to see if the drugs can shrink the tumor enough for less extensive surgery. **You may be eligible if...** - You are 18 or older with locally advanced basal cell carcinoma of the head and neck - Your tumor cannot be removed without major disfigurement (e.g., significant removal of ear, nose, lip, eye, or facial nerve) - Your general health score (performance status) is 0 or 1 - Your blood counts and organ function are adequate **You may NOT be eligible if...** - You have had radiation therapy to this area in the past 6 months - You have another active cancer (with some exceptions) - You are on immune-suppressing medications or have had an organ transplant - You have a serious connective tissue disorder - You have active tuberculosis, hepatitis B, C, or HIV - You have had immunotherapy before for this cancer - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.